Articles Vol. 66 No. CĐ7-HNKH Bệnh viện K 22/05/2025

16. SURVEY OF THE SITUATION CARE OF MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB REGIMENS

Do Huyen Nga1,2, Tran Thi Huyen1,2, Nguyen Thanh Tung1,2, Hoang Thi Thu Huyen1,2
1 K Hospital
2 Bệnh viện K
Corresponding author: tranthuhuyenbvk@gmail.com
DOI: 10.52163/yhc.v66iCD7.2397
21 Views
16 Downloads
Keywords
Multiple myeloma Caregiving
Abstract

Objectives: To evaluate the current status of care for multiple myeloma patients treated with bortezomib-containing chemotherapy regimens at the Hematologic Oncology Department, K Hospital.

Subjects and methods: A prospective descriptive study conducted on 76 Multiple myeloma patients received bortezomib-containing regimens at Hematologic Oncology Department, K Hospital from May 2019 to October 2022.

Results: Mean age was 58.76; Male/female ratio 0.9; The majority of patients admitted to the hospital with PS=1 status accounted for 40.8%; the proportion of PS 2-4 patients accounted for 27.5%; Main symptom was bone pain, accounting for 84.2%; The rate of good basic care reached 56.6%; The group of patients with good care reduces the risk of side effects with p<0.05; PS and VAS pain score after treatment were improved compared to before treatment with p<0.001. Conclusion: Caregiving is an important element in the treatment of multiple myeloma to help improve the quality of treatment, quality of life and reduce complications.

References
[1]
Lê Văn Quảng (2019), "Hướng dẫn chăm sóc người bệnh ung thư", Nhà xuất bản Y học, pp. 115-134. Google Scholar
[2]
Thanh Vân France Nguyen (2014), "A longitudinal analysis of patient satisfaction with care and quality of life in ambulatory oncology based on the OUT-PATSAT35 questionnaire", BMC Cancer, p. 42. Google Scholar
[3]
Ann E Engebretson (2013), "Comparable Outcomes With Bortezomib-Cyclophosphamide-Dexamethasone (VCD) and Bortezomib-Lenalidomide-Dexamethasone (VRD) For Initial Treatment Of Newly Diagnosed Multiple Myeloma (MM)", Blood. 122(21), pp. 3178-3184. Google Scholar
[4]
Durie BG, Hoering A, Abidi MH, et al., (2017), "Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial", Lancet. 389, p. 519. Google Scholar
[5]
Jacob P Laubach (2021), "Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", Uptodate, pp. 1-21. Google Scholar
[6]
Philippe Moreau, Cyrille Hulin, and Margaret Macro et al. (2016), "VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial", Blood, pp. 2569–2574. Google Scholar
[7]
S Vincent Rajkumar (2020), "Multiple myeloma: Overview of management", Uptodate, pp. 1-23. Google Scholar
[8]
T.C. Kouroukis (2014), "Bortezomib in multiple myeloma: systematic review and clinical considerations", Curr Oncol. 21(4), pp. 573–603. Google Scholar